New hope for nighttime cluster headaches: Low-Sodium drug enters trial
NCT ID NCT06950281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether low sodium oxybate (Xywav) can reduce nighttime cluster headache attacks in people with chronic cluster headache. About 52 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug lowers the number of headaches that occur during sleep.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low sodium oxybate (Xywav)
- What this could lead to
- If it works, this could provide a new treatment option to reduce painful nighttime cluster headache attacks.
- What could go wrong
- This is an early phase 2 trial with only 52 participants, so results may not apply to everyone. The drug may cause side effects or not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC CLUSTER HEADACHE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.